Suppr超能文献

人类P2Y1受体:作为识别激动剂和拮抗剂识别位点工具的分子建模与定点诱变

Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites.

作者信息

Moro S, Guo D, Camaioni E, Boyer J L, Harden T K, Jacobson K A

机构信息

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.

出版信息

J Med Chem. 1998 Apr 23;41(9):1456-66. doi: 10.1021/jm970684u.

Abstract

The molecular basis for recognition by human P2Y1 receptors of the novel, competitive antagonist 2'-deoxy-N6-methyladenosine 3', 5'-bisphosphate (MRS 2179) was probed using site-directed mutagenesis and molecular modeling. The potency of this antagonist was measured in mutant receptors in which key residues in the transmembrane helical domains (TMs) 3, 5, 6, and 7 were replaced by Ala or other amino acids. The capacity of MRS 2179 to block stimulation of phospholipase C promoted by 2-methylthioadenosine 5'-diphosphate (2-MeSADP) was lost in P2Y1 receptors having F226A, K280A, or Q307A mutations, indicating that these residues are critical for the binding of the antagonist molecule. Mutation of the residues His132, Thr222, and Tyr136 had an intermediate effect on the capacity of MRS 2179 to block the P2Y1 receptor. These positions therefore appear to have a modulatory role in recognition of this antagonist. F131A, H277A, T221A, R310K, or S317A mutant receptors exhibited an apparent affinity for MRS 2179 that was similar to that observed with the wild-type receptor. Thus, Phe131, Thr221, His277, and Ser317 are not essential for antagonist recognition. A computer-generated model of the human P2Y1 receptor was built and analyzed to help interpret these results. The model was derived through primary sequence comparison, secondary structure prediction, and three-dimensional homology building, using rhodopsin as a template, and was consistent with data obtained from mutagenesis studies. We have introduced a "cross-docking" procedure to obtain energetically refined 3D structures of the ligand-receptor complexes. Cross-docking simulates the reorganization of the native receptor structure induced by a ligand. A putative nucleotide binding site was localized and used to predict which residues are likely to be in proximity to agonists and antagonists. According to our model TM6 and TM7 are close to the adenine ring, TM3 and TM6 are close to the ribose moiety, and TM3, TM6, and TM7 are near the triphosphate chain.

摘要

采用定点突变和分子模拟技术,探究了新型竞争性拮抗剂2'-脱氧-N6-甲基腺苷3',5'-二磷酸(MRS 2179)被人P2Y1受体识别的分子基础。在跨膜螺旋结构域(TMs)3、5、6和7中的关键残基被丙氨酸或其他氨基酸取代的突变受体中,测定了该拮抗剂的效力。在具有F226A、K280A或Q307A突变的P2Y1受体中,MRS 2179阻断2-甲硫基腺苷5'-二磷酸(2-MeSADP)促进的磷脂酶C刺激的能力丧失,这表明这些残基对于拮抗剂分子的结合至关重要。His132、Thr222和Tyr136残基的突变对MRS 2179阻断P2Y1受体的能力有中等程度的影响。因此,这些位置似乎在识别该拮抗剂中具有调节作用。F131A、H277A、T221A、R310K或S317A突变受体对MRS 2179表现出的表观亲和力与野生型受体相似。因此,苯丙氨酸131、苏氨酸221、组氨酸277和丝氨酸317对于拮抗剂识别并非必不可少。构建并分析了人P2Y1受体的计算机生成模型,以帮助解释这些结果。该模型通过一级序列比较、二级结构预测和三维同源性构建得出,以视紫红质为模板,与诱变研究获得的数据一致。我们引入了一种“交叉对接”程序,以获得配体-受体复合物能量优化的三维结构。交叉对接模拟了由配体诱导的天然受体结构的重组。定位了一个假定的核苷酸结合位点,并用于预测哪些残基可能靠近激动剂和拮抗剂。根据我们的模型,TM6和TM7靠近腺嘌呤环,TM3和TM6靠近核糖部分,TM3、TM6和TM7靠近三磷酸链。

相似文献

引用本文的文献

1
Drug-like Antagonists of P2Y Receptor Subtypes: An Update.P2Y 受体亚型的类药拮抗剂:最新进展
J Med Chem. 2025 May 8;68(9):9057-9083. doi: 10.1021/acs.jmedchem.5c00249. Epub 2025 Apr 27.
5
A Adenosine Receptors: Protective vs. Damaging Effects Identified Using Novel Agonists and Antagonists.A 腺苷受体:使用新型激动剂和拮抗剂确定的保护作用与损伤作用
Drug Dev Res. 1998 Nov-Dec;45(3-4):113-124. doi: 10.1002/(SICI)1098-2299(199811/12)45:3/4<113::AID-DDR5>3.0.CO;2-S. Epub 1999 Mar 1.
10
The Molecular Mechanism of P2Y1 Receptor Activation.P2Y1 受体激活的分子机制。
Angew Chem Int Ed Engl. 2016 Aug 22;55(35):10331-5. doi: 10.1002/anie.201605147. Epub 2016 Jul 27.

本文引用的文献

2

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验